Pasithea Therapeutics Corp. $KTTA

By Microcap Ledger desk · CIK 0001841330

Facts as of Oct 11, 2026, 08:16 AM UTC. Built from SEC filings and our own data. Small caps move fast; check the latest filings.

Snapshot

Exchange: Nasdaq Capital Market
Sector: Pharmaceutical Preparations
Headquarters: Miami Beach, FL
Fiscal year end: December 31
Shares outstanding: 33,414,448 [10-Q 2026-08-14]
as of 2026-08-12

Sources: [10-K 2026-03-30]

What the company doesAI summary of filing

Pasithea Therapeutics Corp. is a clinical-stage biotechnology company developing small-molecule treatments for RASopathies, MAPK pathway-driven tumors, and other diseases including central nervous system disorders. The company's lead product candidate, PAS-004, is a next-generation MEK inhibitor currently in Phase 1 clinical trials for advanced cancer and a Phase 1/1b trial for neurofibromatosis type 1 plexiform neurofibromas in adults; the company also has a discovery-stage program (PAS-001) targeting complement component 4A for schizophrenia. Pasithea generates no revenue and is pre-revenue, conducting clinical development and preclinical studies to advance its pipeline toward regulatory approval. [10-K 2026-03-30]

Segments: PAS-004 (MEK 1/2 inhibitor - lead program), PAS-001 (C4A inhibitor - schizophrenia discovery program)

Financial health

From XBRL company facts (USD)
Period	Revenue	Net income	Operating cash flow	Cash	Filing
6 months to Jun 2026	—	−$8.14M	−$9.49M	$45.66M	[10-Q 2026-08-14]
FY ended Dec 2025	—	−$20.43M	−$15.21M	$55.16M	[10-K 2026-03-30]
FY ended Dec 2024	—	−$13.90M	−$13.92M	$6.92M	[10-K 2026-03-30]

Quarterly cash burn: −$4.75M
Cash runway Estimate: ~28.9 months

Capital structure and dilution

Summary only. How these instruments work: Dilution & financing desk.

Share count
Date	Shares outstanding	Filing
2024-11-11	1,266,427	[10-Q 2024-11-13]
2025-03-20	2,705,263	[10-K 2025-03-24]
2025-05-12	7,443,577	[10-Q 2025-05-15]
2025-08-12	7,443,577	[10-Q 2025-08-14]
2025-11-12	7,443,577	[10-Q 2025-11-13]
2026-03-24	24,939,948	[10-K 2026-03-30]
2026-05-13	33,414,448	[10-Q 2026-05-15]
2026-08-12	33,414,448	[10-Q 2026-08-14]

Shelf registration: S-1 filed 2025-11-18; declared effective 2025-11-28 [S-1 2025-11-18]

Listing status

Current status: 3 Form 8-K Item 3.01 filing(s) in the last 24 months, most recent 2026-08-21. Item 3.01 covers delisting notices, failures to meet a listing rule and listing transfers; read the filing for which one.

Date	Event	Details	Deadline	Filing
2026-08-21	8-K Item 3.01	Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing	—	[8-K 2026-08-21]
2026-02-20	8-K Item 3.01	Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing	—	[8-K 2026-02-20]
2025-06-27	8-K Item 3.01	Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing	—	[8-K 2025-06-27]

More on deficiency notices and uplistings: Listing status desk.

Who owns it

Recent Form 4 transactions
Date	Insider	Type	Shares	Price	Filing
2026-06-17	Coastlands Capital Lp	buy	100,000	$0.53	[4 2026-06-22]

Catalysts and calendar

Recent filings and releases
Date	Type	Title
2026-09-16	8-K	Other events
2026-09-09	8-K	Shareholder vote results
2026-08-21	8-K	Listing notice or transfer
2026-08-14	10-Q	Quarterly report
2026-08-14	13G/A	Beneficial ownership report (5%+ holder)
2026-08-07	DEF 14A	Proxy statement
2026-07-31	13G/A	Beneficial ownership report (5%+ holder)
2026-07-29	PRE 14A	Proxy statement
2026-07-01	13G/A	Beneficial ownership report (5%+ holder)
2026-06-23	13G	Beneficial ownership report (5%+ holder)
2026-05-15	10-Q	Quarterly report
2026-05-15	13G/A	Beneficial ownership report (5%+ holder)

Facts as of Oct 11, 2026, 08:16 AM UTC. Small caps move fast; check the latest filings.